Skip to main content
ENCell Co., Ltd. logo

ENCell Co., Ltd. — Investor Relations & Filings

Ticker · 456070 ISIN · KR7456070002 KO Manufacturing
Open in API
Filings indexed 90 across all filing types
Latest filing 2026-03-11 Major Shareholding Noti…
Country KR South Korea
Listing KO 456070

About ENCell Co., Ltd.

http://www.encellinc.com/en/

ENCell Co., Ltd. is a biopharmaceutical company specializing in advanced cell and gene therapies (CGT). The company's primary focus is providing Contract Development and Manufacturing Organization (CDMO) services, supported by globally recognized GMP facilities. Its offerings include process development, manufacturing, and contract quality testing (CQT) for a diverse portfolio of advanced therapies, including MSC, CAR-T, CAR-NK, and iPSC-derived cell therapies. ENCell leverages proprietary technologies such as the ROCKET Platform for multi-product GMP production and a next-generation stem cell platform designed to enhance yield and efficacy. In addition to its CDMO business, the company develops its own therapeutic pipeline. This internal research and development focuses on next-generation stem cell treatments, cancer immunotherapy, and AAV-based gene therapies, with a program for Duchenne Muscular Dystrophy in development.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, specifically due to the exercise of stock options. This type of filing is categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-03-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of an executive (Jeon Hong-bae) at Encell Co., Ltd., specifically noting the exercise of stock options. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2026-03-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when company insiders (executives or major shareholders) change their shareholdings. This corresponds to the 'Director's Dealing' category in the provided classification schema.
2026-03-11 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details changes in share ownership by NH Investment & Securities and its special related parties in the company 'EnCell'. This document type is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-03-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This is a standard regulatory filing in South Korea used to disclose insider trading or changes in share ownership by company directors and major shareholders. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2026-02-12 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (근감소증 환자를 대상으로 EN001의 유효성 및 안전성 평가를 위한 다기관, 무작위배정, 이중눈가림, 위약대조, 제1/2상 임상시험계획 변경승인신청)
Regulatory Filings Classification · 95% confidence The document is a formal regulatory disclosure from a Korean company (EnCell) regarding an application for a change in clinical trial plans submitted to the Ministry of Food and Drug Safety (MFDS). It details the clinical trial design, objectives, and regulatory status. Since it does not fit into specific financial reporting categories like 10-K or IR, and is a standard regulatory announcement regarding operational/clinical developments, it is classified as a Regulatory Filing (RNS). Q1 2026
2026-02-03 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.